NCT06222580 2026-03-13
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
Clinical Trials
4 trialsNCT07463651 2026-03-11
TROPHY-15
The First Affiliated Hospital of Soochow University
Phase 3 Not yet recruiting
NCT05756777 2026-03-05
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07407140 2026-03-02
VAG-3+7-G
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting